Efficacy and Safety of Perampanel Monotherapy in Chinese Patients with Focal-onset Seizures: A Single-center, Prospective, Real-world Observational Study

Overview

Journal Epilepsia Open

Date 2023 Sep 4

PMID 37661647

Authors

Haiyan Ma

Haitao Zhu

Fangqing Chen

Yiqing Yang

Xuefeng Qu

Honghao Xu

Lu Yang

Rui Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Efficacy and safety of perampanel monotherapy for treating focal-onset seizures (FOS) has been barely studied in China. This observational study aimed to evaluate the efficacy and safety of perampanel monotherapy in treating Chinese patients with FOS.

Methods: This single-center, prospective, real-world observational study enrolled patients aged ≥4 years with FOS who visited the Epilepsy Out-Patient Clinic of Nanjing Brain Hospital affiliated to Nanjing Medical University from January 2020 to December 2021. All patients were treated with perampanel monotherapy. Seizure-freedom rates after 6 and 12 months of treatment were calculated. Adverse events (AEs) were recorded.

Results: Seventy patients with FOS were enrolled. The mean maintenance perampanel dose was 4.64 ± 1.55 mg/day. The 6- and 12-month retention rates of perampanel monotherapy were 78.6% (55/70) and 70.0% (49/70), respectively. The 6- and 12-month seizure-freedom rates were 69.84% (44/63) and 65.08% (41/63), respectively. Patients with focal to bilateral tonic-clonic seizures had significantly higher 6-month and numerically higher 12-month seizure freedom rates than patients with focal impaired awareness seizures (P = 0.046 and P = 0.204, respectively). Twenty-six (37.1%) patients experienced treatment-emergent AEs, and the most common AE was dizziness. Four (5.7%) patients withdrew from the study due to AEs. No new safety concern was observed.

Significance: This is the first prospective study on the efficacy and safety of perampanel monotherapy in treating Chinese patients with FOS, and perampanel monotherapy was effective and safe in treating Chinese patients aged ≥4 years with FOS up to 12 months. More multicenter, real-world studies with large sample sizes and longer follow-ups are needed to further evaluate the long-term efficacy and safety of perampanel monotherapy.

Citing Articles

Clinical efficacy and safety of perampanel monotherapy as primary anti-seizure medication in the treatment of pediatric epilepsy: A single-center, prospective, observational study.

Gu Y, Li Y, Li W, Chen F, Wu C, Chen J Epilepsia Open. 2024; 9(6):2209-2218.

PMID: 39292178 PMC: 11633688. DOI: 10.1002/epi4.13043.

Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4-12 years: a real-world study.

Zeng Q, Xia X, Jiang L, Chen J, Liu Y, Hu Y J Neurol. 2024; 271(7):4566-4576.

PMID: 38717610 DOI: 10.1007/s00415-024-12416-y.

Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study.

Ma H, Zhu H, Chen F, Yang Y, Qu X, Xu H Epilepsia Open. 2023; 8(4):1474-1483.

PMID: 37661647 PMC: 10690709. DOI: 10.1002/epi4.12823.

References

Villanueva V, Garces M, Lopez-Gonzalez F, Rodriguez-Osorio X, Toledo M, Salas-Puig J . Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res. 2016; 126:201-10. DOI: 10.1016/j.eplepsyres.2016.08.001. View

Inoue Y, Kaneko S, Hsieh P, Meshram C, Lee S, Abdul Aziz Z . A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy. Epilepsia. 2019; 60 Suppl 1:60-67. DOI: 10.1111/epi.14645. View

Maguire M, Ben-Menachem E, Patten A, Malhotra M, Ngo L . A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. Epilepsy Behav. 2021; 126:108483. DOI: 10.1016/j.yebeh.2021.108483. View

Rogawski M . The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia. 2013; 54 Suppl 2:33-40. DOI: 10.1111/epi.12182. View

Santamarina E, Bertol V, Garayoa V, Garcia-Gomara M, Garamendi-Ruiz I, Giner P . Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. Seizure. 2020; 83:48-56. DOI: 10.1016/j.seizure.2020.09.026. View

Yamamoto T, Gil-Nagel A, Wheless J, Kim J, Wechsler R . Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence. Epilepsy Behav. 2022; 136:108885. DOI: 10.1016/j.yebeh.2022.108885. View

Tyrlikova I, Brazdil M, Rektor I, Tyrlik M . Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures. Expert Rev Neurother. 2018; 19(1):5-16. DOI: 10.1080/14737175.2019.1555474. View

De Biase S, Gigli G, Nilo A, Romano G, Valente M . Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. Expert Opin Drug Metab Toxicol. 2018; 15(2):93-102. DOI: 10.1080/17425255.2019.1560420. View

Husni R, Ngo L, Senokuchi H, Patten A, Hiramatsu H, Watanabe K . Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM). Epilepsia Open. 2021; 7(1):59-66. PMC: 8886102. DOI: 10.1002/epi4.12551. View

10.

Ma H, Zhu H, Chen F, Yang Y, Qu X, Xu H . Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study. Epilepsia Open. 2023; 8(4):1474-1483. PMC: 10690709. DOI: 10.1002/epi4.12823. View

11.

Nishida T, Lee S, Wu T, Tiamkao S, Dash A . Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations. Epilepsia. 2019; 60 Suppl 1:47-59. DOI: 10.1111/epi.14644. View

12.

Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M . Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015; 46(2):110-6. DOI: 10.1055/s-0035-1546276. View

13.

Kwan P, Mintzer S, Laurenza A, Patten A, Cartwright K . Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies. Epilepsy Behav Case Rep. 2018; 9:1-5. PMC: 5916525. DOI: 10.1016/j.ebcr.2017.11.001. View

14.

Zhang R, Qiao S, Fang X, Wang K, Shi Y, Du Q . Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study. Front Neurol. 2021; 12:731566. PMC: 8435584. DOI: 10.3389/fneur.2021.731566. View

15.

Abril Jaramillo J, Estevez Maria J, Giron Ubeda J, Vega Lopez O, Calzado Rivas M, Perez Diaz H . Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON). Epilepsy Behav. 2019; 102:106655. DOI: 10.1016/j.yebeh.2019.106655. View

16.

Toledano Delgado R, Garcia-Morales I, Parejo-Carbonell B, Jimenez-Huete A, Herrera-Ramirez D, Gonzalez-Hernandez A . Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry. Epilepsia. 2020; 61(6):1109-1119. DOI: 10.1111/epi.16548. View

17.

Ettinger A, LoPresti A, Yang H, Williams B, Zhou S, Fain R . Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015; 56(8):1252-63. PMC: 4758397. DOI: 10.1111/epi.13054. View

18.

Steinhoff B, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A . Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54(8):1481-9. DOI: 10.1111/epi.12212. View

19.

Gil-Nagel A, Burd S, Toledo M, Sander J, Lebedeva A, Patten A . A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 2017; 54:61-66. DOI: 10.1016/j.seizure.2017.10.015. View

20.

Jing S, Shiba S, Morita M, Yasuda S, Lin Y . A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects. Clin Drug Investig. 2023; 43(3):155-165. PMC: 10011319. DOI: 10.1007/s40261-022-01241-8. View